A

Amgen

Makes biotech medicines for serious illnesses

Data Sciences - Information and Data Architecture Manager

Full-TimeUpdated on 10/24/2026
No salary listed
Senior, Expert
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Data & AnalyticsData Management

About the job

Requirements
  • A Master's or Bachelor's degree and 8–12 years of experience as a Product Owner, Platform Owner, or Service Owner are required.
  • Strong problem-solving, analytical, and critical-thinking skills are required to address complex data challenges.
  • A deep understanding of pharmaceutical industry data, including Process Development, Manufacturing, Engineering Quality, Supply Chain, and Operations, is required.
  • Advanced skills in semantic modeling, RDF, OWL, SHACL, and ontology development in TopBraid and/or Protégé are required.
  • Demonstrated experience creating knowledge graphs with semantic RDF technologies such as Stardog and testing models with real data is required.
  • High proficiency with RDF, SPARQL, Connected Data concepts, and interacting with triple stores is required.
  • High proficiency in facilitating, capturing, and organizing collaborative discussions through tools such as Lucidchart and Confluence is required.
  • Expertise in FAIR data principles and their application in healthcare and pharmaceutical data models is required.
  • Exceptional interpersonal, business analysis, facilitation, and communication skills are required.
  • The ability to interpret complex regulatory and operational requirements into data models is required.
  • Analytical thinking for problem-solving in a highly regulated environment is required.
  • The ability to adapt to and prioritize multiple projects in a dynamic setting is required.
  • A strong appreciation for customer- and user-centric product design thinking is required.
Responsibilities
  • Ensure successful delivery of connected data initiatives aligned with the Operations Data Strategy roadmap.
  • Lead conversations with business stakeholders to elucidate semantic models of pharmaceutical business concepts, aligned definitions, and relationships; negotiate and debate across stakeholders to drive alignment and create system-independent information models using a data-centric approach aligned with business data domains.
  • Design, develop, and deploy a connected data ecosystem across Operations using semantic modeling, R2RML, SPARQL, Generative AI, large language models, and GraphRAG.
  • Provide technical leadership in Python-based development, SQL-based data transformation, SPARQL retrieval, and AI system design.
  • Develop comprehensive business information models and ontologies that capture industry-specific concepts, including CMC, Clinical, and Operations data.
  • Facilitate whiteboarding sessions with business subject matter experts to elicit knowledge, drive interoperability across pharmaceutical domains, and interface between data producers and consumers.
  • Educate and mentor peers on the practical use and differentiating value of Connected Data and FAIR+ data principles, and champion standards for master data and reference data.
  • Formalize data models in RDF as OWL and SHACL ontologies that interoperate with one another and relevant industry standards such as FHIR and IDMP for healthcare data exchange.
  • Build a broad semantic knowledge graph that threads data together across end-to-end business processes and enables transformation to data-centricity and new ways of working.
  • Guide development of intelligent systems that combine structured and unstructured data, semantic models, and knowledge graphs.
  • Apply pragmatic semantic abstraction to simplify diverse pharmaceutical and healthcare data patterns effectively.
  • Drive adoption of FAIR data principles, data-centric design, and semantic interoperability across solutions.
Desired Qualifications
  • Experience in regulatory data modeling and compliance requirements in the pharmaceutical domain is desirable.
  • Familiarity with pharmaceutical lifecycle data (PLM), including product development and regulatory submissions, is desirable.
  • Knowledge of supply chain and operations data modeling in the pharmaceutical industry is desirable.
  • Proficiency in integrating data from various sources, such as LIMS, EDC systems, and MES, is desirable.
  • Hands-on data analysis and wrangling experience, including SQL-based data transformation and solving integration challenges arising from differences in data structure, meaning, or terminology, is desirable.
  • Expertise in FHIR data standards and their application in healthcare and pharmaceutical data models is desirable.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.